NDA 202860 · Vero Biotech INC
Genosyl
Nitric Oxide · Inhalation · Vasodilator
OrphanLast checked: Nov 20, 2026Latest source record: Dec 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 20, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
478
75 Phase 3, 30 recruiting
FAERS reports
3,897
2,237 serious, 941 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 11, 2025.
GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. GENOSYL ® is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents ( 1 ).
Mechanism: Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature. GENOSYL appears to increase the partial pressure of arterial oxygen (PaO 2 ) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2019 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
- GENOSYL · NITRIC OXIDE 800PPM · GAS, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitric Oxide" as an intervention, any sponsor and status, largest first.
- Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary BypassPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT06702553 · 3,650 participants (planned) · Start May 19, 2025 · Primary completion Mar 31, 2028
Drug: Nitric Oxide Gas; Standard Care Arm · For: Nitric Oxide; Cardiac Surgery; Cardiopulmonary Bypass and 1 more
Sites: Boston, Massachusetts; Xi'an, China; Tomsk, Russia
- The Efficacy of Nitric Oxide in Stroke (ENOS) TrialPivotal-lookingStatus unknown
University of NottinghamAcademic, hospital or other
NCT00989716 · 3,500 participants (planned) · Start Jul 2001 · Primary completion Oct 2013
Drug: Transdermal glyceryl trinitrate patch; Pre-stroke antihypertensives · For: Stroke
Sites: Nottingham, United Kingdom
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term PregnanciesPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00930618 · 1,409 participants · Start Jun 2009 · Primary completion Dec 2013
Drug: IMN; Placebo · For: Prolonged Pregnancy; Nulliparity
Sites: Paris, France
- Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 InfectionPivotal-lookingTerminated
Sanotize Research and Development corp.Industry
NCT05109611 · 1,389 participants · Start Nov 20, 2021 · Primary completion Jan 30, 2024
Drug: Nitric Oxide · For: SARS-CoV-2 Infection
Sites: Oshawa, Canada; Angoda, Sri Lanka; Galle, Sri Lanka · 6 sites in all
- Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)Pivotal-lookingCompleted
Apex BioscienceIndustry
NCT00021502 · 1,000 participants · Start Mar 2001 · Primary completion Aug 2003
Drug: pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) · For: Shock; Systemic Inflammatory Response Syndrome
- Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled AsthmaPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01238861 · 964 participants · Start Dec 2010 · Primary completion Mar 2013
Drug: Benralizumab 2 mg; Benralizumab 20 mg and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 74 sites in all
- De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic HerniaPivotal-lookingRecruiting
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT05213676 · 900 participants (planned) · Start Nov 1, 2025 · Primary completion Oct 31, 2030
Drug: Inhaled Nitric Oxide (iNO) use · For: Congenital Diaphragmatic Hernia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Irvine, California · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event780
- device malfunction637
- underdose476
- device issue424
- drug ineffective314
- off label use237
- death232
- product use issue210
- condition aggravated180
- oxygen saturation decreased167
- respiratory failure139
- pulmonary hypertension137
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 9 |
| 2006 | 17 |
| 2007 | 71 |
| 2008 | 21 |
| 2009 | 16 |
| 2010 | 19 |
| 2011 | 31 |
| 2012 | 9 |
| 2013 | 40 |
| 2014 | 35 |
| 2015 | 44 |
| 2016 | 47 |
| 2017 | 45 |
| 2018 | 72 |
| 2019 | 96 |
| 2020 | 124 |
| 2021 | 430 |
| 2022 | 588 |
| 2023 | 466 |
| 2024 | 687 |
| 2025 | 655 |
| 2026 | 374 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treating asthma patients with probiotics: a systematic review and meta-analysis.
Xie Q, Yuan J, Wang Y · Nutr Hosp 2023 · Meta-Analysis, Systematic Review
- Inhaled nitric oxide and postoperative outcomes in cardiac surgery with cardiopulmonary bypass: A systematic review and meta-analysis.
Yan Y, Kamenshchikov N, Zheng Z, et al. · Nitric Oxide 2024 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia.
Zinellu A, Tommasi S, Carru C, et al. · Transl Psychiatry 2024 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis of macrolides in the management of adult patients with asthma.
Ohnishi H, Otani T, Kanemitsu Y, et al. · Allergol Int 2024 · Meta-Analysis, Systematic Review
- Inhaled nitric oxide in acute bronchiolitis: A systematic review and meta-analysis.
Kuitunen I, Renko M · Pediatr Pulmonol 2024 · Meta-Analysis, Systematic Review
- Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial.
Nathan SD, Rajicic N, Dudenhofer R, et al. · Ann Am Thorac Soc 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Vero Biotech INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.